NOVELIXHealthcare Research, Analytics & Technology
NOVELIX PHARMACEUTICALS LIMITE — Profit & Loss Statement
₹55.78
-3.48%
NOVELIX PHARMACEUTICALS LIMITE Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 0.07 Cr | -44544.61 | — |
| Tax Rate For Calcs | 0.31 | 0.30 | 0.30 | 0.00 | — |
| Normalized EBITDA | 0.15 Cr | -0.25 Cr | -0.76 Cr | 0.76 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 0.08 Cr | 0.01 Cr | -0.06 Cr | -1.56 Cr | — |
| Reconciled Depreciation | 0.04 Cr | 0.04 Cr | 0.06 Cr | 0.07 Cr | — |
| Reconciled Cost Of Revenue | 29.57 Cr | 3.84 Cr | 1.35 Cr | 0.81 Cr | — |
| EBITDA | 0.15 Cr | -0.25 Cr | -0.52 Cr | -0.52 Cr | — |
| EBIT | 0.11 Cr | -0.29 Cr | -0.57 Cr | -0.59 Cr | — |
| Normalized Income | 0.08 Cr | 0.01 Cr | -0.23 Cr | -0.29 Cr | — |
| Net Income From Continuing And Discontinued Operation | 0.08 Cr | 0.01 Cr | -0.06 Cr | -1.56 Cr | — |
| Total Expenses | 30.61 Cr | 4.51 Cr | 1.98 Cr | 1.43 Cr | — |
| Diluted NI Availto Com Stockholders | 0.08 Cr | 0.01 Cr | -0.06 Cr | -1.56 Cr | — |
| Net Income Common Stockholders | 0.08 Cr | 0.01 Cr | -0.06 Cr | -1.56 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 0.08 Cr | 0.01 Cr | -0.06 Cr | -1.56 Cr | — |
| Net Income Including Noncontrolling Interests | 0.08 Cr | 0.01 Cr | -0.06 Cr | -1.56 Cr | — |
| Net Income Continuous Operations | 0.08 Cr | 0.01 Cr | -0.06 Cr | -1.56 Cr | — |
| Tax Provision | 0.04 Cr | 0.01 Cr | 14540.00 | -54720.00 | — |
| Pretax Income | 0.12 Cr | 0.02 Cr | -0.06 Cr | -1.57 Cr | — |
| Other Non Operating Income Expenses | 0.02 Cr | 0.31 Cr | 0.52 Cr | 0.55 Cr | — |
| Operating Income | 0.11 Cr | -0.29 Cr | -0.57 Cr | -0.59 Cr | — |
| Operating Expense | 1.04 Cr | 0.67 Cr | 0.63 Cr | 0.62 Cr | — |
| Other Operating Expenses | 0.93 Cr | 0.48 Cr | 0.15 Cr | 0.15 Cr | — |
| Depreciation And Amortization In Income Statement | 0.04 Cr | 0.04 Cr | 0.06 Cr | 0.07 Cr | — |
| Depreciation Income Statement | 0.04 Cr | 0.04 Cr | 0.06 Cr | 0.07 Cr | — |
| Gross Profit | 1.14 Cr | 0.39 Cr | 0.05 Cr | 0.03 Cr | — |
| Cost Of Revenue | 29.57 Cr | 3.84 Cr | 1.35 Cr | 0.81 Cr | — |
| Total Revenue | 30.72 Cr | 4.22 Cr | 1.40 Cr | 0.84 Cr | — |
| Operating Revenue | 30.72 Cr | 4.22 Cr | 1.40 Cr | 0.84 Cr | — |
| Total Unusual Items | — | -0.04 Cr | 0.24 Cr | -1.27 Cr | -2.95 Cr |
| Total Unusual Items Excluding Goodwill | — | -0.04 Cr | 0.24 Cr | -1.27 Cr | -2.95 Cr |
| Net Interest Income | — | 0.20 Cr | 0.27 Cr | 0.30 Cr | 0.27 Cr |
| Interest Income | — | 0.20 Cr | 0.27 Cr | 0.30 Cr | 0.33 Cr |
| Rent Expense Supplemental | — | 0.01 Cr | 0.01 Cr | 0.02 Cr | 0.06 Cr |
| Diluted Average Shares | — | 1.04 Cr | 0.81 Cr | 0.81 Cr | 0.81 Cr |
| Basic Average Shares | — | 1.04 Cr | 0.81 Cr | 0.81 Cr | 0.81 Cr |
| Diluted EPS | — | 0.01 | -0.07 | -1.93 | -4.62 |
| Basic EPS | — | 0.01 | -0.07 | -1.93 | -4.62 |
| Special Income Charges | — | -0.10 Cr | 0.00 | 0.22 Cr | -2.96 Cr |
| Other Special Charges | — | -0.04 Cr | — | 0.02 Cr | — |
| Write Off | — | 0.14 Cr | 0.00 | -0.24 Cr | 2.96 Cr |
| Net Non Operating Interest Income Expense | — | 0.20 Cr | 0.27 Cr | 0.30 Cr | 0.27 Cr |
| Total Other Finance Cost | — | 2700.00 | 2700.00 | 1170.00 | 0.01 Cr |
| Interest Income Non Operating | — | 0.20 Cr | 0.27 Cr | 0.30 Cr | 0.33 Cr |
| Selling General And Administration | — | 0.10 Cr | 0.09 Cr | 0.08 Cr | 0.20 Cr |
| Selling And Marketing Expense | — | 0.02 Cr | 0.03 Cr | 0.03 Cr | 0.05 Cr |
| General And Administrative Expense | — | 0.08 Cr | 0.06 Cr | 0.05 Cr | 0.15 Cr |
| Rent And Landing Fees | — | 0.01 Cr | 0.01 Cr | 0.02 Cr | 0.06 Cr |
| Interest Expense | — | — | — | 0.06 Cr | 0.05 Cr |
| Minority Interests | — | — | — | 0.23 Cr | — |
| Interest Expense Non Operating | — | — | — | 0.06 Cr | 0.05 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on NOVELIX PHARMACEUTICALS LIMITE
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.